CSF3 and mixed phenotype acute leukemia: In accordance with these findings, we retrospectively analyzed MPAL patients who received the hybrid protocol based on cladribine, cytarabine, granulocyte colony-stimulating factor (G-CSF), and mitoxantrone (CLAG-M).